Furthermore, the CDK4/6 inhibitor abemaciclib enhances the efficacy of anti-PD-L1 ICIs by augmenting antigen presentation and T cell activation in human breast cancer cells (263). The gene discussed is CDK4; the disease is breast carcinoma.